PHILADELPHIA, May 9, 2011 /PRNewswire-USNewswire/ -- Building on its extensive laboratory research using magnetically guided nanoparticles to deliver drugs to diseased blood vessels, The Children's Hospital of Philadelphia has just spun off its first startup company, Vascular Magnetics, Inc. (VMI).
By licensing its technology to VMI, a new company formed to develop the lab findings into a commercially viable therapy, the Hospital aims to create a novel, greatly needed treatment for peripheral artery disease (PAD). Characterized by blocked arteries, primarily in the legs, PAD affects more than 27 million older adults in North America and Europe, with diabetes patients and smokers at particularly high risk. Current treatments for PAD, including drug-eluting stents, are ineffective, with re-blockage of the arteries occurring at a high rate.
In addition to being the Hospital's first startup company, the program targets patients outside the Hospital's usual pediatric age group. "While our first target group is adult patients, the technique represents a new platform technology, potentially adaptable to delivering a variety of therapies to children as well as adults," says the technology's inventor, Robert J. Levy, M.D., the William J. Rashkind Endowed Chair in Pediatric Cardiology at The Children's Hospital of Philadelphia.
Levy co-founded VMI with Richard S. Woodward, Ph.D., the company's Chief Executive Officer. The two first joined forces through the QED Proof-of-Concept Program sponsored by the University City Science Center in West Philadelphia. The goal of the QED Program, the nation's first multi-institutional proof-of-concept program for life sciences technologies, is to accelerate research from academic laboratories into the marketplace. A unique feature of this program is that academic scientists such as Levy are partnered with experienced business advisors such as Woodward, who has a background that includes developing nanoparticles and polymeric coatings.
"The Science Center is proud to have played a role in the launch of Vascular Magnetics," said Stephen S. Tang, Ph.D., MBA, president and CEO of the University City Science Center. "VMI's launch is helping to prove our concept that the early addition of business advice is a key element of the tech transfer puzzle."
In a series of animal studies over the past decade, Levy and his team at Children's Hospital have investigated his new approach to stent-based therapy. They have developed nanoparticles, extremely tiny spheres made of a biodegradable polymer impregnated with iron oxide. Under a low-power, uniform magnetic field, much lower than that produced by existing MRI machines, magnetic forces drive the nanoparticles into metal stents and the surrounding artery. The nanoparticles carry a therapeutic payload of the drug paclitaxel, which is released into the surrounding blood vessel tissue in order to slow arterial re-blockage. In 2008, Forbes magazine named Levy's work a promising "disruptive technology," one that might eventually supplant conventional technology, in this case, drug-eluting stents.
As they advance the technique to human trials, Levy and Woodward envision a future therapy called Vascular Magnetic Intervention™ which would serve as an adjunct to artery stenting. A physician would open and stent the blocked artery and then insert a catheter tipped with an expandable magnetic targeting device. The targeting device would be expanded against the walls of the artery.
A magnetic field is then applied to the leg, and paclitaxel-containing magnetic nanoparticles would be administered through the catheter. The targeting device develops strong magnetic gradients that force the nanoparticles into the wall of the artery. After treatment and removal of the catheter, the wall of the artery is uniformly coated with the nanoparticles, which slowly biodegrade and release the drug. The uniform coating provides a higher dose of drug than is achievable with a drug-eluting stent. In addition, the technique could be used to re-treat arteries where the stents have become re-blocked.
The technology, said Levy, is highly adaptable. Instead of paclitaxel, it could deliver other therapeutic compounds, DNA for site-specific gene therapy, therapeutic cells, or other treatments. In addition to treating PAD, the technique might carry paclitaxel to narrowed coronary arteries, chemotherapy drugs to a tumor, or other medications to a bile duct or a urinary tract. Eventually, said Levy, the technology could be applied to types of pediatric heart disease, such as primary pulmonary hypertension or heart defects.
As its lab research continues, Vascular Magnetics is moving ahead to attract venture capital. "Our plan is to prove the efficacy of this therapy in humans by late 2015," said Woodward. "The revenue projections for the company suggest sales of over a billion dollars per year within about four years after commercial launch."
"Besides the great potential medical benefit in PAD, commercial success for this technology could enhance our mission of improving children's health—by setting the stage for developing and investing in innovative therapies for children," added Ellen Purpus, Ph.D., director, Office of Technology Transfer at The Children's Hospital of Philadelphia.
About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 516-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
About the QED Program: The University City Science Center's QED Program is a multi-institutional proof-of-concept program that provides business development support for academic researchers developing early-stage life science technologies with high commercial potential. The key goal is to retire the business risk in these early-stage projects, increasing their attractiveness to follow-on investment by established life science companies and private investors. The QED Program integrates four elements that are critical to successfully and efficiently performing early-stage proof-of-concept technology development: business advice, bridge funding, market drivers and guidance to exit. The QED Program is currently open to researchers at 19 academic and research institutions in Pennsylvania, New Jersey and Delaware.Contact: John Ascenzi
Contact: Richard S. Woodward, Ph.D.The Children's Hospital of Philadelphia
Vascular Magnetics, Inc.Phone: (267) 426-6055
Phone: (856) 753-7650Ascenzi@email.chop.edu
|SOURCE The Children's Hospital of Philadelphia|
Copyright©2010 PR Newswire.
All rights reserved